Skip to main content

Table 2 Targeting ferroptosis in breast cancer- currently available pharmaceutical agents

From: Targeting ferroptosis in breast cancer

Drug Origin Improvement/function Phenomenon and characteristics Year Reference
Ironomycin Salinomycin Accumulating and sequestering iron in lysosomes Iron overload and reactive oxygen species overgeneration 2017 [51]
CSO-SS-Cy7-Hex/SPION/Srfn Sorafenib, iron Combined iron and sorafenib Iron overload, intracellular depletion of glutathione and reactive oxygen species overgeneration 2019 [106]
Erastin@FA-exo Erastin TNBC targetting, increased biocompatibility Intracellular depletion of glutathione and reactive oxygen species overgeneration 2019 [107]
MnO2@HMCu2-xS nanocomposites Mn2+, rapamycin Combined Fenton-like reaction by Mn2+ and autophagy by rapamycin Iron overload and reactive oxygen species overgeneration 2019 [108]
Drug-organics-inorganics self-assembled nanosystem Doxorubicin, iron, tannic acid Combined chemotherapy, ferroptosis and superoxide dismutase (SOD)-like reaction Iron overload and reactive oxygen species overgeneration 2019 [109]
Nanoparticle ferritin-bound erastin and rapamycin Erastin, rapamycin Combined ferroptosis and autophagy GPX4 downregulation and lipid peroxidation accumulation 2019 [110]
Ascorbate plus nanocarrier loading Fe3+ and RSL3 Ascorbate, iron, RSL3 Increased specificity to target cancer cells by ascorbate Iron overload, inhibition of GPX4 and reactive oxygen species overgeneration 2019 [111]